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Background: Co-trimoxazole is a broad-spectrum antibiotic associated with hyperkalemia.
Objective: To determine the incidence of hyperkalemia and its risk factors in patients 
receiving co-trimoxazole.
Materials and Methods: A retrospective observational study involving all patients who 
received co-trimoxazole between 1 January 2012 and 1 January 2013 was conducted. 
Subjects were identified through a list generated from a computerized pharmacy system. 
The patients’ demographic and clinical characteristics were retrieved from electronic medical 
records. Data were analyzed using univariate and multivariate logistic regression.
Results: One hundred sixty-one patients fulfilled the eligibility criteria. Of these, 46 (28.6%) 
experienced hyperkalemia. Around 35 (76%) of the patients who experienced hyperkalemia 
received co-administered medications that might induce hyperkalemia. The co- 
administration of co-trimoxazole with other medications that may induce hyperkalemia 
was found to be associated with higher incidence of hyperkalemia when compared to co- 
trimoxazole administration alone [adjusted OR 3.2, 95% CI (1.4–7.3), p=0.005]. 
Additionally, age > 60 years was associated with an increased risk of hyperkalemia when 
compared to younger age group 18–39 years [adjusted OR 6.5, 95% CI (2.1–19.7); p=0.001].
Conclusion: Co-trimoxazole use is associated with high incidence of hyperkalemia, espe-
cially among older patients and those receiving it in combination with other medications that 
might contribute to hyperkalemia development such as calcineurin inhibitors and β-blockers.
Keywords: co-trimoxazole, co-administration, hyperkalemia, risk factors, adverse drug 
reaction
Introduction
Co-trimoxazole, a broad-spectrum antibiotic comprising trimethoprim and sulfa-
methoxazole, is widely used for the treatment and prophylaxis of Gram- 
positive bacteria, Gram-negative bacteria, and some parasitic infections.1 
However, co-trimoxazole use has been associated with hyperkalemia, a severe 
and potentially fatal adverse drug reaction (ADR).2,3 A study reported that more 
than half (53%) of the patients with acquired immunodeficiency syndrome (AIDS) 
who were treated with co-trimoxazole for pneumocystis jiroveci infection devel-
oped hyperkalemia.4 In addition, emerging evidence suggests that co-trimoxazole 
can precipitate a life-threatening condition called BRaSh syndrome. It is 
a combination of bradycardia, renal impairment, drug-induced AV blockage, 
shock, and hyperkalemia.5 The proposed mechanism of co-trimoxazole-induced 
hyperkalemia is mediated through the blockage of amiloride-sensitive sodium 
channels in the distal tubule, due to the structural similarity of trimethoprim with 
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potassium-sparing diuretics, leading to the impairment of 
renal potassium excretion.2 Age and co-administered med-
ications have been recognized as risk factors for co- 
trimoxazole-induced hyperkalemia.3 Evidence suggests 
that concurrent administration of drugs such as angioten-
sin-converting enzyme inhibitors (ACE-Is), angiotensin-II 
receptor blockers (ARBs), β-blockers, and spironolactone 
can increase serum potassium concentration, leading to 
increased incidence of severe hyperkalemia, hospitaliza-
tion, and mortality.3 ACE-Is, ARBs, and spironolactone 
have an additional mechanism of inducing hyperkalemia 
by decreasing the serum concentration of aldosterone, 
resulting in reabsorbing potassium at the distal renal 
tubule.6 Several studies have also identified age as 
a factor potentially increasing the risk of hyperkalemia 
and mortality.3 When potassium serum concentration 
reaches 6 mEq/L or more, treatment interruption and 
close monitoring are warranted to avoid cardiac toxicity.2 
Limiting potassium intake and avoiding other medications 
that might contribute to hyperkalemia are approaches to 
consider when the potassium level is controlled below 6 
mEq/L.2 Despite the clinical significance of co- 
trimoxazole-induced hyperkalemia, this ADR has been 
neglected by many clinicians, and no clear guidelines are 
available to monitor patients.
Aim of the Study
This study aimed to investigate the incidence of hyperka-
lemia among patients who received co-trimoxazole and 
had normal serum potassium concentrations at baseline 
and to identify potential risk factors for the hyperkalemia.
Materials and Methods Study Design
This was a retrospective observational study of patients who 
received co-trimoxazole for therapeutic or prophylactic indi-
cations at Hamad General Hospital (HGH) in Qatar. The 
therapeutic indications included treatment of acute sponta-
neous bacterial peritonitis (SBP), mild diabetic foot infection, 
toxoplasmosis, urinary tract infection, and Pneumocystis 
pneumonia. The prophylactic indications included bite 
wound infection prophylaxis, SBP long-term secondary pre-
vention, and Pneumocystis pneumonia prevention in immu-
nocompromised patients. Patients were identified through 
a computerized pharmacy system, via an automated report 
generated between 1 January 2012 and 1 January 2013. 
Baseline potassium serum level was considered as any level 
within one week prior to initiation of co-trimoxazole; all 
subsequent levels were follow-up. Hyperkalemia was defined 
as serum potassium level above 5.5 mEq/L.2 Patients’ elec-
tronic medical records were reviewed to obtain the laboratory 
parameters (serum creatinine and serum potassium levels at 
baseline and follow-up). Patients’ medication histories were 
reviewed to identify any co-administered medications that 
has the potential to induce hyperkalemia.
Ethics Approval
This study was reviewed and approved by the Institutional 
Review Board (IRB) of the Medical Research Center at 
Hamad Medical Corporation (HMC's MRC) in Qatar 
(approval number: #14425/14). This is a retrospective obser-
vational chart review and obtaining informed consent to 
participate in the study from the research subjects was not 
applicable. In such cases, the IRB typically grants a waiver 
of consent. Further, all patient data accessed complied with 
relevant data protection and privacy regulations in Qatar.
Eligibility Criteria
Adult patients (≥18 years) with normal renal function 
(GFR ≥60 mL/min/1.73m2) who received co-trimoxazole 
during the study period and had documented potassium 
serum levels at baseline and during follow- 
up were included. Patients who received less than two 
doses of co-trimoxazole and/or had no potassium follow- 
up were excluded from the study.
Data Collection
Electronic medical records were reviewed to obtain relevant 
data at baseline and follow-up: demographics (age and sex); 
dose, frequency, and duration of co-trimoxazole; comorbid 
conditions, and concurrent medications potentially affecting 
potassium serum levels including β-blockers (selective and 
non-selective), calcineurin inhibitors, heparin, ACE-I, 
ARBs, potassium-sparing diuretics (spironolactone, eplere-
none), nonsteroidal anti-inflammatory drugs (NSAIDs), and 
antifungals (fluconazole). In addition, relevant laboratory 
data like serum potassium and serum creatinine concentra-
tions were collected. Baseline potassium and creatinine 
levels were considered as any level within one week prior 
to initiation of co-trimoxazole. Any potassium or creatinine 
level within the first week of the short-treatment course or 
within one month of the long-term prophylactic indications 
were considered as follow-up readings.
Data Analysis
Data were analyzed using SPSS version 18 (IBM SPSS® 
Statistics for Windows; IBM Corp, Armonk, New York, 
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USA). Both descriptive and inferential statistics were 
applied for the data analysis. The 95% confidence intervals 
(CIs) for each mean were also calculated. Chi-square was 
used to compare the incidence of hyperkalemia between 
different factors. Univariate and multivariate logistic regres-
sion analyses were conducted to determine the association 
between risk factors and development of co-trimoxazole- 
induced hyperkalemia and compute adjusted and unadjusted 
odds ratios (ORs). The factors included in the multivariate 
logistic regression analysis were age, gender, total daily dose 
[the once and twice daily doses of the double strength (DS) 
tablet 800/160 mg], and the co-administered medications. 
The level of statistical significance was defined as p≤ 0.05.
Results
Of the 500 patients reviewed, 121 patients were excluded 
due to impaired renal function (GFR <60 mL/min/1.73 m2), 
168 did not have follow-up data, and 50 patients received 
less than two doses of co-trimoxazole. One hundred sixty- 
one patients who fulfilled the inclusion criteria were included 
(Figure 1). Of these, 57.1% (n=92) were male and 57.1% 
(n=92) were prescribed other medications known to contri-
bute to hyperkalemia. Around 24% of the patients had 
hypertension, 56% had diabetes, and 46% were status-post 
organ transplant. The patients were divided into two groups 
based on the co-trimoxazole (DS tablet 800/160 mg) dosing 
frequency; once daily vs twice daily dosing regimen. The 
number of patients in each group was comparable (Table 1).
Hyperkalemia (potassium serum concentration >5.5 mEq/ 
L) was observed in 46 (28.6%) patients, of whom, 25/46 
(54.3%) were in the twice-daily dosing group. Thirty-five 
(76%) of the patients who developed hyperkalemia were 
receiving concurrent medications known to increase potas-
sium serum levels (Table 1). Receiving co-trimoxazole in 
combination with β-blockers, calcineurin inhibitors alone or 
in combination with β-blockers was significantly associated 
with higher incidence of hyperkalemia when compared to 
receiving co-trimoxazole alone [OR 3.2, 95% CI (1.1–9.7), 
p=0.035, OR 3.2, 95% CI (1.2–8.3), p=0.019, OR 3.4, 95% CI 
(1.2–9.8), p=0.024] (Table 2). Both selective and non-selective 
Excluded with reasons (n=339): 
• 121 patients were 
excluded due to 
impaired renal function
• 168 did not have 
follow-up data
• 50 patients received 
less than two doses of 
co-trimoxazole.
161 patients fulfil the inclusion criteria included in the study:
1- Aged > 18 years 
2- Received more than 2 doses of co-trimoxazole
3- Had baseline and follow-up potassium serum level
4- Normal renal function  
46 patients developed hyperkalemia
500 participants 
were screened 
Figure 1 A flow chart of the screening process.
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β-blockers were considered in the analysis [40 patients 
received selective β -blockers (atenolol, metoprolol, or biso-
prolol) and 13 received the non-selective ones (propranolol or 
carvedilol)]. Of note, during the study period, no patients were 
identified to co-administer potassium-sparing diuretics, 
NSAIDs, or potassium supplements with the co-trimoxazole. 
Moreover, patients with age >60 years were more prone to 
develop hyperkalemia when compared to younger age groups 
18–39 years [OR 6.37, 95% CI (2.6–18.8), p=0.001]
After adjusting the confounders with the multivariate 
logistic regression analysis, only age and co-administered 
medications were found to be significant. Patients with age 
>60 years were more prone to develop hyperkalemia when 
compared to the younger age group 18–39 years [adjusted OR 
6.5, 95% CI (2.1–19.7), p=0.001]. Moreover, the middle age 
group (40–60 years) was also found to have higher incidence 
of hyperkalemia than the younger age group 18–39 years 
[adjusted OR 3.5, 95% CI (1.2–10.5), p=0.023]. In addition, 
the co-administration of other medications that may induce 
hyperkalemia was found to be associated with higher inci-
dence of hyperkalemia when compared to those receiving co- 
trimoxazole alone [adjusted OR 3.2, 95% CI (1.4–7.3), 
p=0.005].
Discussion
Almost one-third of the patients receiving co-trimaxazole 
developed hyperkalemia, with age >60 years identified as 
high-risk. In addition, co-administration of medications that 
are known to raise potassium serum level increased the risk of 
hyperkalemia by three folds [adjusted OR 3.2, 95% CI (1.4–-
7.3), p=0.005]. However, dosing frequency did not signifi-
cantly influence the hyperkalemia incidence.
A previous study by Fralick et al affirmed that co- 
trimoxazole use with an ACE-I or ARB was associated 
with increased risk of sudden death due to severe hyperka-
lemia [OR 1.38: 95% CI (1.09 to 1.76)] when compared 
with amoxicillin.3 In our study, the incidence of hyperkale-
mia was 3-fold higher amongst patients who received med-
ications that increase serum potassium level. However, the 
incidence of hyperkalemia amongst patients who received 
ACE-Is or ARBs vs those who received co-trimoxazole 
alone was 8.6% (n=3) vs 15.9% (n=11) (Tables 1 and 2). 
The small group of patients who received ACE-Is/ARBs 
(n=16 out 161) could be the reason for the deviation from 
published literature. Furthermore, among the β-blocker 
users, Weir et al found that the rate of hospitalization 
among co-trimoxazole users was considerably higher 
when compared to amoxicillin (OR 5.1; 95% CI 2.8 to 
9.4).8 Evidence indicates that non-selective β-blockers are 
more commonly associated with hyperkalemia than the 
cardioselective ones.9 However, there are some evidence 
that suggested the potential of selective β-blockers like 
metoprolol,10,11 bisoprolol,12 and atenolol13 to induce 
hyperkalemia.11,12 In the current study, both selective and 
non-selective β-blockers were included, where 38% (8) of 
β-blocker users developed hyperkalemia.
Table 1 Incidence of Hyperkalemia in Patients Receiving Co-Trimoxazole (n = 161)
Total 
(n=161)





● Hyperkalemia in the entire population regardless of the interacting drugs 46 (28.6%) 21 (28%) 25 (29%)
● Hyperkalemia in patients receiving co-trimoxazole without interacting drugs 11 (24%) 7 (33%) 4 (16%)
● Hyperkalemia in patients receiving co-trimoxazole with other medications that are 
known to influence potassium level
35 (76%) 14 (67%) 21 (84%)
Incidence of hyperkalemia among different co-administered medication groups
Total 
(n=35)
Once Daily (n=14) Twice Daily 
(n=21)
*β-blocker 8 (22.9%) 2 (14.3%) 6 (28.6%)
**Immunosuppressant agent + β-blocker 9 (25.7%) 3(21.4%) 6 (28.6%)
Heparin 3 (8.6%) 3 (21.4%) 0 (0%)
***ACEIs/ARBs 3 (8.6%) 2 (14.3%) 1 (4.8%)
** Calcineurin inhibitors 12 (34.3%) 4 (28.6%) 8 (38.1%)
Notes: *β-blocker: bisoprolol, metoprolol, carvedilol, atenolol, propranolol. ** Calcineurin inhibitors: cyclosporine, tacrolimus. ***ACEIs/ARBs: Lisinopril, enalapril, 
irbesartan, valsartan, losartan.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                    
Risk Management and Healthcare Policy 2021:14 522
Al AdAwi et al                                                                                                                                                       Dovepress
A recent cohort study showed a 0.28 mmol/l (95% CI 
0.03–0.53, p=0.031) increase in serum potassium level 
was associated with co-trimoxazole use compared to cef-
triaxone use. It is noteworthy that the population of the 
study was older adults [mean age 73.8 (12.5) years]; 
hence, the incidence of hyperkalemia was more 
pronounced.14 A post-hoc analysis of a randomized con-
trolled trial showed that amongst older patients [mean 
age 72 (8.5) years old], co-trimoxazole raised the mean 
potassium level by 0.21 mmol/l at 6 weeks treatment time 
when compared to placebo.15 Additionally, a nested 
case–control study of a cohort of older patients (>66 
years) concluded that the potential for hyperkalemia- 
associated hospitalization was increased seven-fold 
among older patients receiving ACE-Is or ARBs 
(adjusted OR, 6.7; 95% CI, 4.5–10.0).8 Studies have 
also demonstrated that older people receiving co- 
trimoxazole in combination with other medications 
known to contribute to hyperkalemia are at higher risk 
of hyperkalemia,3,7 which is consistent with our findings 
that advanced age was associated with higher risk of 
hyperkalemia.
In this study, the co-administration of calcineurin 
inhibitors, either alone or in combination with β-block-
ers, was significantly associated with increased inci-
dence of hyperkalemia. Several studies and case 
reports found that tacrolimus and cyclosporine cause 
elevation in plasma potassium concentration, which can 
be further augmented by co-administration of an ACE-I 
or an ARB.5,16
Table 2 Univariate Logistic Regression Analysis for Factors Associated with Hyperkalemia in Patients Receiving Co-Trimoxazole
Variables Percentage of Hyperkalemia (n) Unadjusted OR 95% CI p-value
Age
18−39 10.2% (5) 1
40–60 32.3% (20) 4.19 (1.4–12.2) 0.009
>60 42% (21) 6.37 (2.6–18.8) 0.001
Sex
Female 26.1% (18) 1 (0.6–2.5) 0.5
Male 30.4% (28) 1.24
Dosing frequency
Once daily (n=75) 28% (21) 0.95 (0.5–1.9) 0.9
Twice daily (n=86) 29% (25) 1
Taking other medications listed below
Yes (n=92) 38% (35) 3.2 (1.5–7) 0.003
No (n=69) 15.9% (11) 1
β-blocker alone
Yes (n=21) 38% (8) 3.2 (1.1–9.7) 0.035
No (n=69) 15.9% (11) 1
ACEIs & ARBs
Yes (n=10) 30% (3) 2.3 (0.5–10.1) 0.3
No (n=69) 15.9% (11) 1
Heparin
Yes (n=6) 50% (3) 5.3 (0.9–29.6) 0.059
No (n=69) 15.9% (11) 1
Immunosuppressant agent alone
Yes (n=32) 37.5% (12) 3.2 (1.2–8.3) 0.019
No (n=69) 15.9% (11) 1
Immunosuppressant agent + β-blocker
Yes (n=23) 39.1% (9) 3.4 (1.2–9.8) 0.024
No (n=69) 15.9% (11) 1
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A review by Perazella et al reported that co- 
trimoxazole can cause hyperkalemia regardless of dose.2 
However, a retrospective study showed that hyperkalemia 
incidence was more frequent with the higher doses of co- 
trimoxazole.17 In this study, the results failed to confirm 
a correlation between hyperkalemia incidence and the total 
daily doses of co-trimoxazole (once daily or twice daily 
doses of the DS 800/160 mg).
There is some evidence that pharmacists have a crucial 
role in monitoring drug therapy to detect and prevent 
ADRs.18 Hence, pharmacists can contribute to active mon-
itoring of potassium levels and additionally educating 
patients on the potential for interactions with other medi-
cation, conditions, and food.
This study has the inherent limitations of a retrospective 
study design in that only the specific data collected and 
recorded during routine clinical practice could be captured. 
While we excluded those with renal impairment, hyperka-
lemia could be a result of other factors such as excess 
dietary potassium intake, renal and adrenal insufficiencies, 
and other factors. The limited sample size may have meant 
that the study was underpowered for the comparison made; 
hence, the results should be interpreted with caution. There 
may also be issues with generalizability to other popula-
tions and settings. Furthermore, the study was completed 
several years earlier, although clinical practice is relatively 
unchanged hence the data and findings remain valid. There 
is a need for prospective studies with adequate sample sizes 
and more frequent monitoring of potassium and serum 
creatinine levels.
Conclusion
Co-trimoxazole administration was associated with an 
increased risk of hyperkalemia especially among older 
patients and those receiving other co-administered medica-
tions that may induce hyperkalemia. Caution should be 
exercised when co-trimoxazole is used in older people 
and patients receiving other medications affecting potas-
sium levels such as calcineurin inhibitors and the combi-
nation of calcineurin inhibitors and β-blockers.
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